Vanguard Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-1,970,034
| Closed | -$94.6M | – | 4151 |
|
|
2020
Q1 | $94.6M | Buy |
1,970,034
+99,241
| +5% | +$4.62M | ﹤0.01% | 1558 |
|
|
2019
Q4 | $87.8M | Buy |
1,870,793
+53,460
| +3% | +$2.36M | ﹤0.01% | 1842 |
|
|
2019
Q3 | $43M | Buy |
1,817,333
+253,221
| +16% | +$7.5M | ﹤0.01% | 2140 |
|
|
2019
Q2 | $47M | Buy |
1,564,112
+253,966
| +19% | +$5.82M | ﹤0.01% | 2135 |
|
|
2019
Q1 | $29.3M | Buy |
1,310,146
+228,680
| +21% | +$4.92M | ﹤0.01% | 2333 |
|
|
2018
Q4 | $19.7M | Buy |
1,081,466
+342,129
| +46% | +$5.37M | ﹤0.01% | 2445 |
|
|
2018
Q3 | $13.4M | Buy |
739,337
+61,929
| +9% | +$734K | ﹤0.01% | 2780 |
|
|
2018
Q2 | $6.74M | Buy |
677,408
+7,835
| +1% | +$54.1K | ﹤0.01% | 3087 |
|
|
2018
Q1 | $3.56M | Buy |
669,573
+277,685
| +71% | +$1.98M | ﹤0.01% | 3273 |
|
|
2017
Q4 | $3.33M | Buy |
391,888
+35,375
| +10% | +$435K | ﹤0.01% | 3272 |
|
|
2017
Q3 | $5.21M | Buy |
356,513
+9,911
| +3% | +$150K | ﹤0.01% | 3105 |
|
|
2017
Q2 | $6.5M | Buy |
346,602
+76,349
| +28% | +$1.72M | ﹤0.01% | 2987 |
|
|
2017
Q1 | $5.75M | Buy |
270,253
+170,478
| +171% | +$3.26M | ﹤0.01% | 3008 |
|
|
2016
Q4 | $1.51M | Buy |
+99,775
| New | +$1.36M | ﹤0.01% | 3453 |
|
Other funds holding RARX
Vanguard Group's RARX Position: Q2 2020 in Review
Vanguard Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,970,034 shares — an estimated $94.6M sold.
Vanguard Group first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $94.6M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Vanguard Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Vanguard Group sold 1,970,034 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $94.6M.
- Vanguard Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- Vanguard Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $94.6M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Vanguard Group's 13F filing for Q2 2020, filed 14 Aug 2020.